JPMorgan’s reinvestment strategy and tech focus boost long-term value, with 2025 growth targets and a $300–$320 fair value. See more on JPM stock here.
JPMorgan top boss Jamie Dimon signaled support for former Federal Reserve Governor Kevin Warsh as the next chair of the U.S.
Wall Street trading got off to a mixed start on Friday after both the Dow Jones and S&P 500 wrapped up the previous session ...
The excitement of selecting stocks diminishes rapidly when market volatility strikes. Wise financial advisors remain ...
US stocks finished in mixed fashion on Thursday, though the Dow Jones Industrial Average surged to a new all-time high on the ...
Galaxy’s onchain debt deal, where JP Morgan acted as arranger, was settled in USDC stablecoin and backed by Coinbase and ...
AC Immune said its immunotherapy showed the potential to slow the progression of Parkinson’s disease, based on preliminary ...
Partnering Platform Now Open for RegistrationSAN FRANCISCO--(BUSINESS WIRE)--#biotechshowcase--Biotech Showcase™ returns to ...
SAN FRANCISCO, CA / ACCESS Newswire / December 9, 2025 / Longwood Healthcare Leaders will convene top biopharmaceutical leaders at San Francisco CEO for two days of discussion, January 10-11, 2026, ...
Fintel reports that on December 4, 2025, Canaccord Genuity maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) ...
Fintel reports that on December 3, 2025, Morgan Stanley downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...
Morgan Stanley has downgraded Regeneron Pharmaceuticals ( REGN) to equal-weight from overweight saying that the stock is fairly valued. The bank maintained its price target of $767 (~3% upside based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback